Synthesis of benzimidazole derivatives as potent inhibitors for α-amylase and their molecular docking study in management of type-II diabetes

• Published in: Journal of Molecular Structure
• Main Author: Hussain S.; Taha M.; Rahim F.; Hayat S.; Zaman K.; Iqbal N.; Selvaraj M.; Sajid M.; Bangesh M.A.; Khan F.; Khan K.M.; Uddin N.; Shah S.A.A.; Ali M.
• Format: Article
• Language: English
• Published: Elsevier B.V. 2021
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101323909&doi=10.1016%2fj.molstruc.2021.130029&partnerID=40&md5=2a3ee29ff71e8775509250548c6f68a0

In the search of potent α-amylase inhibitors, we have synthesized seventeen derivatives of 2-mercaptobenzimidazole bearing sulfonamide (1–17) and evaluated for their α-amylase inhibitory potential. All synthesized compounds display a variable degree of α-amylase activity having IC50 values ranging between 0.90 ± 0.05 to 11.20 ± 0.30 µM when compared with the standard drug acarbose having IC50 value 1.70 ± 0.10 µM. Compound 1, 2, 11, 12 and 14 having IC50 values 1.40 ± 0.10, 1.30 ± 0.05, 0.90 ± 0.05, 1.60 ± 0.05 and 1.60 ± 0.10 µM respectively were found many folds better than the standard drug acarbose. While others derivatives of the series showed good inhibitory potentials. All the synthesized compounds were characterized by HREI-MS, 1H and 13C NMR spectroscopy. Structure activity relationship (SAR) has been established for all newly synthesized analogs. Binding interactions between ligands and active residues of the enzyme were confirmed through molecular docking study. © 2021 Elsevier B.V.